CytomX Therapeutics Inc (CTMX) Stock Analysis

CytomX Therapeutics Inc (CTMX) is a publicly traded company in the HEALTHCARE sector. It trades at $3.16, carries a market capitalization of $751.08M. This page summarizes the public market data, fundamentals, and frequently asked questions for CTMX, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

• Price: $3.16
• Market Cap: $751.08M
• EPS: $-0.52
• 52-Week High: $8.21
• 52-Week Low: $1.72

Market Sentiment

CytomX Therapeutics Inc currently has a Bullish sentiment score of 0.22.

About CytomX Therapeutics Inc

CytomX Therapeutics, Inc., based in South San Francisco, California, is a pioneering biopharmaceutical company focused on revolutionizing cancer treatment through its proprietary Probody™ technology platform. This innovative approach aims to create highly selective therapeutics that reduce off-tumor effects while enhancing targeted anti-tumor activity, addressing critical unmet needs in oncology. With a promising pipeline of product candidates at various clinical stages, CytomX is well-positi...

GNG Research Analysis

GNG Research scores CytomX Therapeutics Inc (CTMX) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for CTMX.

Frequently Asked Questions

Does CTMX pay dividends?

CytomX Therapeutics Inc (CTMX) does not currently pay a regular dividend.

What is CTMX's market cap?

CytomX Therapeutics Inc (CTMX) has a market capitalization of $751.08M with a current stock price of $3.16.